BIOSYNEX overview

BIOSYNEX SA BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY 23-Oct-2024 / 18:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. PRESS RELEASE Medford N.Y USA/Strasbourg France, Oct 23, 2024 CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY...

Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex PR Newswire MILWAUKEE, April 20, 2023 MILWAUKEE , April 20, 2023 /PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with Biosynex. Click here to learn how to join the action https://www.ademilaw.com/case/chembio-diagnostics-inc or call Guri Ademi toll-free at...

BIOSYNEX SA BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A. 13-Jan-2023 / 18:00 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A. BIOSYNEX (ISIN : FR0011005933, Mnémonique :ALBIO), a major player in public health, announces the...

Regulatory News: BIOSYNEX (FR0011005933/ Mnemonic : ALBIO) (Paris: ALBIO), a major player in public health, today announces the great success of its capital increase without shareholders' preferential subscription rights for a final amount of € 15 million through an offering to qualified French and international investors (“the Transaction”) carried out by accelerated bookbuilding. The order book was largely covered, based on sustained demand from new and existing institutional investors,...